FEATURED ARTICLE
GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial
On October 7, 2024, Scholar Rock announced that the Phase III clinical trial (SAPPHIRE) of Apitegromab (SRK-015) met its primary endpoint with a statistically significant and clinically...
GDF-8 (Myostatin) antibody Apitegromab achieves success in Phase III clinical trial
On October 7, 2024, Scholar Rock announced that the Phase III clinical trial (SAPPHIRE) of Apitegromab (SRK-015) met its primary endpoint with a statistically significant and clinically...
